Equibles does not estimate personal net worth.
Get an email with a short summary when Axsome Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get AXSM alertsHerriot Tabuteau is recorded as CEO at Axsome Therapeutics, Inc. (AXSM). The newest filing on record that lists Herriot Tabuteau as CEO at Axsome Therapeutics, Inc. (AXSM) is dated April 24, 2026. The proxy statement of Axsome Therapeutics, Inc. reports total compensation of $10,283,492 for Herriot Tabuteau in fiscal 2025, including a base salary of $835,000. Disclosed compensation is on record for 9 fiscal years. Herriot Tabuteau has spoken on 27 earnings calls across 1 company, most recently for Axsome Therapeutics, Inc. on November 2, 2026. Axsome Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Axsome Therapeutics, Inc. includes Nick Pizzie (CFO), Mark Jacobson (COO), Hunter Murdock (General Counsel) and 3 others.
“Axome delivered another robust quarter across our business. Driven by continued commercial progress and advancements in our industry-leading neuroscience pipeline.”
“The second quarter was highly productive for Axome as we grew our commercial business robustly and made important regulatory and clinical progress across our innovative neuroscience pipeline.”
“As a reminder, we'll be launching next month, and Ari touched on the items that are being finalized right now for launch. Do you want to recap those again one more time, right?”
“2025 was a year of significant commercial research and development progress at Axon. Our commercial business is strong, with Avelity achieving sales of over half a billion dollars in its third full year of launch, Genozy Growth Accelerating, and Simbravo Launching, adding a third pillar of growth.”
“Axsome continues to lead in CNS innovation, driven by disciplined execution and a clear focus on sustained growth and value creation. In the third quarter, we delivered strong revenue growth with total revenue of $171 million across our 3 marketed products, representing a 63% increase year-over-year.”
Start not stated–present
Last confirmed April 24, 2026
Biotechnology · Healthcare
CEO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Axsome Therapeutics, Inc. (AXSM) | Chief Executive Officer, President and Chairman of the Board | $835,000 | $10,283,492 |
| 2024 | Axsome Therapeutics, Inc. (AXSM) | Chief Executive Officer, President and Chairman of the Board | $780,000 | $10,364,688 |
| 2023 | Axsome Therapeutics, Inc. (AXSM) | Chief Executive Officer, President and Chairman of the Board | $750,000 | $9,896,629 |
| 2022 | Axsome Therapeutics, Inc. (AXSM) | Chief Executive Officer, President and Chairman of the Board | $685,000 | $8,322,402 |
| 2021 | Axsome Therapeutics, Inc. (AXSM) | Chief Executive Officer, President and Chairman of the Board | $685,000 | $8,054,631 |
| 2020 | Axsome Therapeutics, Inc. (AXSM) | Chief Executive Officer, President and Chairman of the Board | $575,000 | $7,304,689 |
| 2019 | Axsome Therapeutics, Inc. (AXSM) | Chief Executive Officer, President and Chairman of the Board | $435,000 | $4,715,753 |
| 2018 | Axsome Therapeutics, Inc. (AXSM) | Chief Executive Officer and Chairman of the Board | $435,000 | $1,057,425 |
| 2017 | Axsome Therapeutics, Inc. (AXSM) | Chief Executive Officer and Chairman of the Board | $435,000 | $1,123,352 |
